x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011376
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse |
| Applications | IHC-P |
| Product Description | Biotin Rabbit monoclonal antibody [E379] to NF-kB p65. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | RELA |
| UniProt No. | Q04206 |
| Gene ID | 5970 |
| Gene Description | NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at +4 °C short term (1-2 weeks). Upon delivery aliquot. Store at -20 °C. Avoid freeze / thaw cycle. Store In the Dark. |
| Storage Buffer | pH: 7.40; Preservative: 0.02% Sodium azide; Constituents: 30% Glycerol (glycerin, glycerine), 1% BSA, PBS |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
